Gain Therapeutics To Present At Biotech Showcase 2025
Gain Therapeutics (Nasdaq: GANX), a clinical-stage biotechnology company, has announced its participation in Biotech Showcase 2025. Gene Mack, the Company's Chief Financial Officer and Interim Chief Executive Officer, will deliver a corporate presentation featuring their lead drug candidate GT-02287 and the Magellan Drug Discovery Platform.
The presentation is scheduled for Tuesday, January 14, at 9:30am PT in the Yosemite A track at the Hilton San Francisco Union Square. The Biotech Showcase, jointly produced by Demy-Colton and EBD Group, is an investor-focused conference that facilitates networking between executives and investors to promote therapeutic development and investment opportunities.
Gain Therapeutics (Nasdaq: GANX), una società biotecnologica in fase clinica, ha annunciato la sua partecipazione al Biotech Showcase 2025. Gene Mack, il Direttore Finanziario e Amministratore Delegato ad interim dell'azienda, terrà una presentazione aziendale incentrata sul loro principale candidato farmaceutico GT-02287 e sulla Magellan Drug Discovery Platform.
La presentazione è programmata per martedì 14 gennaio alle 9:30 ora pacifica nel percorso Yosemite A presso l'Hilton San Francisco Union Square. Il Biotech Showcase, prodotto congiuntamente da Demy-Colton e EBD Group, è una conferenza focalizzata sugli investitori che facilita il networking tra dirigenti e investitori per promuovere lo sviluppo terapeutico e le opportunità di investimento.
Gain Therapeutics (Nasdaq: GANX), una empresa de biotecnología en etapa clínica, ha anunciado su participación en Biotech Showcase 2025. Gene Mack, el Director Financiero y Director Ejecutivo Interino de la compañía, realizará una presentación corporativa destacando su candidato principal a fármaco GT-02287 y la Magellan Drug Discovery Platform.
La presentación está programada para el martes 14 de enero a las 9:30 a.m. PT en la pista Yosemite A en el Hilton San Francisco Union Square. El Biotech Showcase, producido conjuntamente por Demy-Colton y EBD Group, es una conferencia centrada en inversores que facilita el networking entre ejecutivos e inversores para promover el desarrollo terapéutico y las oportunidades de inversión.
Gain Therapeutics (Nasdaq: GANX)는 임상 단계의 생명공학 회사로 Biotech Showcase 2025에 참여할 것을 발표했습니다. Gene Mack, 회사의 최고 재무 책임자이자 임시 CEO는 그들의 주요 약물 후보인 GT-02287와 Magellan Drug Discovery Platform에 대한 기업 발표를 할 예정입니다.
발표는 1월 14일 화요일 오전 9:30(태평양 표준시) Hilton San Francisco Union Square의 Yosemite A 트랙에서 진행됩니다. Demy-Colton과 EBD Group이 공동으로 제작하는 Biotech Showcase는 치료 개발 및 투자 기회를 촉진하기 위해 경영진과 투자자 간의 네트워킹을 지원하는 투자자 중심의 컨퍼런스입니다.
Gain Therapeutics (Nasdaq: GANX), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation au Biotech Showcase 2025. Gene Mack, le directeur financier et directeur général par intérim de l'entreprise, présentera une conférence d'entreprise mettant en avant leur principal candidat médicament GT-02287 et la plateforme de découverte de médicaments Magellan.
La présentation est prévue pour mardi 14 janvier à 9h30 PT dans la piste Yosemite A au Hilton San Francisco Union Square. Le Biotech Showcase, organisé conjointement par Demy-Colton et EBD Group, est une conférence axée sur les investisseurs qui facilite le réseautage entre les dirigeants et les investisseurs pour promouvoir le développement thérapeutique et les opportunités d'investissement.
Gain Therapeutics (Nasdaq: GANX), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an Biotech Showcase 2025 bekannt gegeben. Gene Mack, der Hauptfinanzbeamte und vorläufige CEO des Unternehmens, wird eine Unternehmenspräsentation halten, die sich auf ihr leitendes Arzneimittelkandidat GT-02287 und die Magellan Drug Discovery Platform konzentriert.
Die Präsentation ist für Dienstag, den 14. Januar, um 9:30 Uhr PT im Yosemite A-Trakt im Hilton San Francisco Union Square angesetzt. Der Biotech Showcase, der gemeinsam von Demy-Colton und EBD Group organisiert wird, ist eine investorenorientierte Konferenz, die Networking zwischen Führungskräften und Investoren fördert, um die therapeutische Entwicklung und Investitionsmöglichkeiten zu unterstützen.
- None.
- None.
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform
BETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Chief Financial Officer and Interim Chief Executive Officer of Gain, will give a corporate presentation at Biotech Showcase 2025, being held January 13-15, 2025, at the Hilton San Francisco Union Square in San Francisco, CA.
Date: Tuesday, January 14
Time: 9:30am PT
Track: Yosemite A (Ballroom Level)
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.
About GT-02287
Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric protein modulator that restores the function of the lysosomal protein enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, and improved motor function and cognitive performance. Additionally, GT-02287 significantly reduced plasma neurofilament light chain (NfL) levels, an emerging biomarker for neurodegeneration.
Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggests that GT-02287 may have the potential to slow or stop the progression of Parkinson’s disease.
Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the offering and uncertainties related to the offerings and the use of proceeds from the offerings. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2023 and Form 10-Q for the quarter ended September 30, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Apaar Jammu and Chuck Padala
ajammu@gaintherapeutics.com
chuck@lifesciadvisors.com
Media Contacts:
Russo Partners
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
FAQ
When and where will Gain Therapeutics (GANX) present at Biotech Showcase 2025?
What will be featured in GANX's presentation at Biotech Showcase 2025?
Who will represent GANX at the Biotech Showcase 2025 presentation?
What is the purpose of the Biotech Showcase 2025 conference where GANX will present?
